1/ Important new research by @KizzyPhD & other @NIAIDNews scientists on the Moderna vaccine in non-human primates.

They gave the primates 2 doses of the Moderna vaccine 4 weeks apart.

And challenged them with Delta variant virus 1 year later.

biorxiv.org/content/10.110…
2/
Gray: unvaccinated
Red: vaccinated

After vaccination, binding antibody levels:
- peaked at 6 weeks
- dropped weeks 6-25
- rate of decline slowed weeks 25-48
3/
Serum neutralizing antibody titers:
- dropped weeks 6-24
- rate of decline slowed weeks 24-48
- were highest vs D614G (early variant)⚫️>Gamma🟢>Beta🔴>Delta🔵
4/ This same pattern was observed with a pseudovirus assay:
- decline in neutralizing antibody titers over time
- lower neutralizing antibody titers against the Delta variant vs the early D614G variant
5/ See also:
6/ Over time, antibody avidity (i.e. the strength of binding to Spike protein) got better 6-24 weeks after vaccination.

This likely reflects somatic hypermutation & affinity maturation.
7/ They also looked at antibody titers in the lungs (bronchoalveolar lavage, BAL) & nose (nasal washes).

Binding antibody titers in the lungs dropped weeks 6-25, & then the rate of decline slowed.
8/ Among vaccinated primates challenged with Delta virus, antibody titers in the lungs⬆️ & peaked by day 4.

Among unvaccinated primates challenged with Delta virus, antibody titers in the lungs⬆️ days 4-14.
9/ Binding antibody titers in the👃🏾peaked later than in the🫁at 25 weeks & then remained stable out to week 42.
10/
Among vaccinated primates challenged with Delta virus, antibody titers in the👃🏾⬇️by day 4.

Among unvaccinated primates challenged with Delta virus, antibody titers in the👃🏾⬆️ by day 14.

Antibodies in the👃🏾may be cleared differently than in the 🫁.
11/ They also used a Spike protein-ACE2 binding inhibition assay to assess antibody function.

Binding in🫁 peaked at 6 weeks after vaccination & declined by 42 weeks.
12/ The Spike protein-ACE2 binding inhibition assay found that binding in👃🏾increased until week 25 & remained elevated at week 42 after vaccination.
13/ They assessed S protein-specific memory B-cells after vaccination with flow cytometry.

The % of S-protein specific memory B-cell responses peaked at 6 weeks after vaccination & then decreased by week 25.
14/ Over the course of a year, Spike protein-binding B-cells shifted from activated memory phenotype to activated/resting/tissue-like memory cells.
15/ Spike protein-specific T-cell responses were also assessed.

Th1 responses were detected at week 6 & ⬇️by week 25. They were low-undetectable by week 42.
16/ Tfh responses were detectable by week 6 & ⬇️by week 42.
17/ Th2 & CD8+ T-cell responses were low after vaccination.
18/ After Delta virus challenge, there was significantly less viral replication in 🫁 by day 4 among vaccinated vs unvaccinated primates.
19/ After Delta virus challenge, there was significantly less viral replication in👃🏾by day 2 among vaccinated vs unvaccinated primates, but the overall reduction in viral replication was less in👃🏾than in 🫁.
20/ Tissue culture infectious dose was also assessed from 🫁&👃🏾samples.

Viral replication in 🫁&👃🏾 of vaccinated primates was lower than for unvaccinated primates.

By day 4 after Delta virus challenge, replication in🫁was undetectable in almost all vaccinated primates.
21/ Viral replication in the 👃🏾of vaccinated primates was lower than for unvaccinated primates, but not zero.
22/ IN SUMMARY:

Unvaccinated and Moderna vaccinated primates were challenged with the Delta variant ~1 year after vaccination.

Four days after challenge, vaccinated primates had NO culturable virus in the lungs, but virus was culturable in the nose.
23/ Antibody-related protection in the lungs is durable but delayed.

It takes time for memory B-cells to rev up & make antibodies.
24/ Note that enough virus made it into the 🫁 of vaccinated primates to elicit a local anamnestic antibody response and a bump in Spike protein-specific B- & T-cell populations.
25/🫁from vaccinated & unvaccinated primates were examined 7 days after Delta virus challenge.

Viral antigen was detected in🫁of all unvaccinated primates & none of the vaccinated primates.

Inflammation was:
- minimal-moderate among vaccinated
- minimal-severe in unvaccinated
26/ Binding & neutralizing antibody titers declined over one year after vaccination leaving the lungs susceptible to viral infection & replication in the first couple days after challenge.

But the local anamnestic response was sufficient to prevent severe disease.
27/ Neutralizing antibodies are a good correlate of protection soon after vaccination.

A year after vaccination, memory B-cells may be a better correlate of protection.
28/ If the goal is to prevent infection in the👃🏾&🫁, it’s likely primates (& people) will need repeated (yearly?) vaccine boosters.

If the goal is to prevent severe disease, protection from the mRNA vaccines appears durable (at least out to 48 weeks).

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with Céline Gounder, MD, ScM, FIDSA

Céline Gounder, MD, ScM, FIDSA Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @celinegounder

25 Oct
1/ There's good evidence that to protect against severe disease, hospitalization, & death, the following would benefit from an additional dose of COVID vaccine:
- immunocompromised persons
- people 60-65+ (? 40+)
- residents of long-term care facilities

nytimes.com/2021/10/25/hea…
2/
3/ What should our goal be with the vaccines?
- Prevention of severe disease, hospitalization, & death
- Prevention of symptomatic infection (which means trying to prevent ALL infections since we can't always predict who'll be symptomatic)
Read 6 tweets
24 Oct
1/ Why can't we just test people to see if they have immunity to SARS-CoV-2 and decide whether they need to be vaccinated based on that test result?

jamanetwork.com/journals/jama/…
2/ Commercially available tests (what you'd get through your doc's office / urgent care clinic) measure binding, not neutralizing antibodies.

While there is a correlation, it's an imperfect one.

We don't know what level of neutralizing antibodies are necessary for protection.
3/ Some tests only pick up antibodies after infection (e.g. antibodies to nucleocapside protein).

Others pick up antibodies after infection or vaccination (e.g. antibodies to spike protein).
Read 7 tweets
22 Oct
1/ Important reporting by @snolen for @nytimes today:
nytimes.com/interactive/20…

We keep being told: "Yes, we know. It's not right. It's a really hard problem. We're doing everything we can."

No, that's not Facebook on disinformation (well, that too).

That's the USG & Moderna.
2/ It makes no sense when you want to maintain control over the technology.

You could TRAIN people how to make mRNA vaccines.
3/ Thanks to @DrTomFrieden, @Public_Citizen, @PrEP4AllNow, & @MSF_USA for beating the drum on this:
Read 25 tweets
22 Oct
1/ On mixing & matching COVID shots, by @KatherineJWu in @TheAtlantic:
theatlantic.com/health/archive…

If you're eligible for an additional dose of COVID vaccine, you can get whichever you want (Pfizer, Moderna, or J&J).
2/ There were only ~50 people in each 9-arm of the NIH mix & match study for a total of less than 500.

Moderna was given full-dose (100 mcg) in the NIH mix & match study, not half-dose (50 mcg) as approved for boosters.
Higher dose➡️more side-effects

Read 5 tweets
21 Oct
1/ Some interesting slides from today's @CDCgov ACIP meeting:
cdc.gov/vaccines/acip/…

Waning immunity?
Or the Delta factor (more infectious, somewhat more immune-evading)?

Some of both.
But in 65+, it's the Delta factor.
2/ Also, those 65+ have a weaker immune response up front.

I'd expect to see the same among immunocompromised persons.

Immunosenescence is a form of immunocompromise.
3/ Why is there ⬇️VE vs hospitalization over time among those among 18-44 yo with 1+ non-immunocompromising chronic conditions?

Confounding by behavior?

If real, this would justify different eligibility criteria by race based on "weathering" argument:
washingtonpost.com/opinions/black…
Read 9 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!

Follow Us on Twitter!

:(